DEXCOM INC (DC4.DE) Stock Fundamental Analysis
Europe - FRA:DC4 - US2521311074 - Common Stock
61.38 EUR
+0.63 (+1.04%)
Taking everything into account, DC4 scores 6 out of 10 in our fundamental rating. DC4 was compared to 59 industry peers in the Health Care Equipment & Supplies industry. DC4 scores excellent on profitability, but there are some minor concerns on its financial health. DC4 is valued quite expensively, but it does show have an excellent growth rating. This makes DC4 very considerable for growth investing!
1. Profitability
1.1 Basic Checks
DC4 had positive earnings in the past year.
In the past year DC4 had a positive cash flow from operations.
Each year in the past 5 years DC4 has been profitable.
DC4 had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
DC4's Return On Assets of 7.80% is fine compared to the rest of the industry. DC4 outperforms 79.66% of its industry peers.
The Return On Equity of DC4 (22.21%) is better than 91.53% of its industry peers.
DC4's Return On Invested Capital of 14.52% is amongst the best of the industry. DC4 outperforms 94.92% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for DC4 is above the industry average of 9.04%.
The 3 year average ROIC (11.25%) for DC4 is below the current ROIC(14.52%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.8% | ||
| ROE | 22.21% | ||
| ROIC | 14.52% |
ROA(3y)7.95%
ROA(5y)8.21%
ROE(3y)23.2%
ROE(5y)22.06%
ROIC(3y)11.25%
ROIC(5y)9.23%
1.3 Margins
DC4 has a Profit Margin of 13.29%. This is in the better half of the industry: DC4 outperforms 76.27% of its industry peers.
DC4's Profit Margin has improved in the last couple of years.
DC4's Operating Margin of 17.22% is fine compared to the rest of the industry. DC4 outperforms 76.27% of its industry peers.
In the last couple of years the Operating Margin of DC4 has grown nicely.
The Gross Margin of DC4 (60.01%) is comparable to the rest of the industry.
DC4's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 17.22% | ||
| PM (TTM) | 13.29% | ||
| GM | 60.01% |
OM growth 3Y10.52%
OM growth 5Y8.87%
PM growth 3Y17.27%
PM growth 5Y15.84%
GM growth 3Y-3.98%
GM growth 5Y-0.72%
2. Health
2.1 Basic Checks
DC4 has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
DC4 has more shares outstanding than it did 1 year ago.
DC4 has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, DC4 has an improved debt to assets ratio.
2.2 Solvency
DC4 has an Altman-Z score of 5.05. This indicates that DC4 is financially healthy and has little risk of bankruptcy at the moment.
DC4 has a better Altman-Z score (5.05) than 83.05% of its industry peers.
DC4 has a debt to FCF ratio of 4.38. This is a neutral value as DC4 would need 4.38 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.38, DC4 is in the better half of the industry, outperforming 61.02% of the companies in the same industry.
DC4 has a Debt/Equity ratio of 0.50. This is a neutral value indicating DC4 is somewhat dependend on debt financing.
DC4 has a worse Debt to Equity ratio (0.50) than 61.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 4.38 | ||
| Altman-Z | 5.05 |
ROIC/WACC1.84
WACC7.87%
2.3 Liquidity
DC4 has a Current Ratio of 1.52. This is a normal value and indicates that DC4 is financially healthy and should not expect problems in meeting its short term obligations.
DC4 has a Current ratio (1.52) which is in line with its industry peers.
A Quick Ratio of 1.35 indicates that DC4 should not have too much problems paying its short term obligations.
The Quick ratio of DC4 (1.35) is better than 66.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.52 | ||
| Quick Ratio | 1.35 |
3. Growth
3.1 Past
The earnings per share for DC4 have decreased by -2.86% in the last year.
Measured over the past years, DC4 shows a very strong growth in Earnings Per Share. The EPS has been growing by 29.25% on average per year.
DC4 shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.30%.
Measured over the past years, DC4 shows a very strong growth in Revenue. The Revenue has been growing by 22.27% on average per year.
EPS 1Y (TTM)-2.86%
EPS 3Y35.38%
EPS 5Y29.25%
EPS Q2Q%11.63%
Revenue 1Y (TTM)9.3%
Revenue growth 3Y18.1%
Revenue growth 5Y22.27%
Sales Q2Q%15.21%
3.2 Future
DC4 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.60% yearly.
The Revenue is expected to grow by 13.90% on average over the next years. This is quite good.
EPS Next Y26.84%
EPS Next 2Y26.2%
EPS Next 3Y24.65%
EPS Next 5Y22.6%
Revenue Next Year14.99%
Revenue Next 2Y15.17%
Revenue Next 3Y14.81%
Revenue Next 5Y13.9%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 41.76, the valuation of DC4 can be described as expensive.
DC4's Price/Earnings is on the same level as the industry average.
When comparing the Price/Earnings ratio of DC4 to the average of the S&P500 Index (26.91), we can say DC4 is valued expensively.
The Price/Forward Earnings ratio is 27.08, which means the current valuation is very expensive for DC4.
The rest of the industry has a similar Price/Forward Earnings ratio as DC4.
DC4's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.92.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 41.76 | ||
| Fwd PE | 27.08 |
4.2 Price Multiples
62.71% of the companies in the same industry are cheaper than DC4, based on the Enterprise Value to EBITDA ratio.
The rest of the industry has a similar Price/Free Cash Flow ratio as DC4.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 48.89 | ||
| EV/EBITDA | 26.02 |
4.3 Compensation for Growth
DC4's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The excellent profitability rating of DC4 may justify a higher PE ratio.
A more expensive valuation may be justified as DC4's earnings are expected to grow with 24.65% in the coming years.
PEG (NY)1.56
PEG (5Y)1.43
EPS Next 2Y26.2%
EPS Next 3Y24.65%
5. Dividend
5.1 Amount
No dividends for DC4!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:DC4 (10/24/2025, 7:00:00 PM)
61.38
+0.63 (+1.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners97.73%
Inst Owner ChangeN/A
Ins Owners0.19%
Ins Owner ChangeN/A
Market Cap24.07B
Revenue(TTM)4.30B
Net Income(TTM)571.50M
Analysts84.57
Price Target89.5 (45.81%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.34%
Min EPS beat(2)-4.09%
Max EPS beat(2)6.77%
EPS beat(4)2
Avg EPS beat(4)-1.87%
Min EPS beat(4)-11.66%
Max EPS beat(4)6.77%
EPS beat(8)6
Avg EPS beat(8)9.43%
EPS beat(12)10
Avg EPS beat(12)14.38%
EPS beat(16)11
Avg EPS beat(16)8.49%
Revenue beat(2)1
Avg Revenue beat(2)0.34%
Min Revenue beat(2)-0.19%
Max Revenue beat(2)0.88%
Revenue beat(4)1
Avg Revenue beat(4)-0.54%
Min Revenue beat(4)-1.66%
Max Revenue beat(4)0.88%
Revenue beat(8)2
Avg Revenue beat(8)-0.78%
Revenue beat(12)5
Avg Revenue beat(12)-0.39%
Revenue beat(16)6
Avg Revenue beat(16)-0.42%
PT rev (1m)0%
PT rev (3m)0.76%
EPS NQ rev (1m)0.42%
EPS NQ rev (3m)0.28%
EPS NY rev (1m)0.14%
EPS NY rev (3m)1.07%
Revenue NQ rev (1m)0.08%
Revenue NQ rev (3m)0.67%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)0.23%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 41.76 | ||
| Fwd PE | 27.08 | ||
| P/S | 6.49 | ||
| P/FCF | 48.89 | ||
| P/OCF | 28.25 | ||
| P/B | 10.84 | ||
| P/tB | 11.34 | ||
| EV/EBITDA | 26.02 |
EPS(TTM)1.47
EY2.39%
EPS(NY)2.27
Fwd EY3.69%
FCF(TTM)1.26
FCFY2.05%
OCF(TTM)2.17
OCFY3.54%
SpS9.46
BVpS5.66
TBVpS5.41
PEG (NY)1.56
PEG (5Y)1.43
Graham Number13.68
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.8% | ||
| ROE | 22.21% | ||
| ROCE | 18.43% | ||
| ROIC | 14.52% | ||
| ROICexc | 53.56% | ||
| ROICexgc | 59.66% | ||
| OM | 17.22% | ||
| PM (TTM) | 13.29% | ||
| GM | 60.01% | ||
| FCFM | 13.27% |
ROA(3y)7.95%
ROA(5y)8.21%
ROE(3y)23.2%
ROE(5y)22.06%
ROIC(3y)11.25%
ROIC(5y)9.23%
ROICexc(3y)35.45%
ROICexc(5y)29.66%
ROICexgc(3y)40.94%
ROICexgc(5y)33.19%
ROCE(3y)14.28%
ROCE(5y)11.73%
ROICexgc growth 3Y55.18%
ROICexgc growth 5Y18.96%
ROICexc growth 3Y50.14%
ROICexc growth 5Y16.58%
OM growth 3Y10.52%
OM growth 5Y8.87%
PM growth 3Y17.27%
PM growth 5Y15.84%
GM growth 3Y-3.98%
GM growth 5Y-0.72%
F-Score6
Asset Turnover0.59
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 4.38 | ||
| Debt/EBITDA | 1.33 | ||
| Cap/Depr | 176.58% | ||
| Cap/Sales | 9.69% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 101.12% | ||
| Profit Quality | 99.88% | ||
| Current Ratio | 1.52 | ||
| Quick Ratio | 1.35 | ||
| Altman-Z | 5.05 |
F-Score6
WACC7.87%
ROIC/WACC1.84
Cap/Depr(3y)175.34%
Cap/Depr(5y)240.83%
Cap/Sales(3y)9.32%
Cap/Sales(5y)10.84%
Profit Quality(3y)97.76%
Profit Quality(5y)73.64%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.86%
EPS 3Y35.38%
EPS 5Y29.25%
EPS Q2Q%11.63%
EPS Next Y26.84%
EPS Next 2Y26.2%
EPS Next 3Y24.65%
EPS Next 5Y22.6%
Revenue 1Y (TTM)9.3%
Revenue growth 3Y18.1%
Revenue growth 5Y22.27%
Sales Q2Q%15.21%
Revenue Next Year14.99%
Revenue Next 2Y15.17%
Revenue Next 3Y14.81%
Revenue Next 5Y13.9%
EBIT growth 1Y6.1%
EBIT growth 3Y30.52%
EBIT growth 5Y33.11%
EBIT Next Year77.25%
EBIT Next 3Y38.83%
EBIT Next 5Y31.4%
FCF growth 1Y22.49%
FCF growth 3Y127.88%
FCF growth 5Y36.21%
OCF growth 1Y28.04%
OCF growth 3Y30.77%
OCF growth 5Y25.76%
DEXCOM INC / DC4.DE FAQ
What is the ChartMill fundamental rating of DEXCOM INC (DC4.DE) stock?
ChartMill assigns a fundamental rating of 6 / 10 to DC4.DE.
Can you provide the valuation status for DEXCOM INC?
ChartMill assigns a valuation rating of 3 / 10 to DEXCOM INC (DC4.DE). This can be considered as Overvalued.
Can you provide the profitability details for DEXCOM INC?
DEXCOM INC (DC4.DE) has a profitability rating of 8 / 10.
What is the earnings growth outlook for DEXCOM INC?
The Earnings per Share (EPS) of DEXCOM INC (DC4.DE) is expected to grow by 26.84% in the next year.